Cidara Therapeutics to Participate in November Investor Conferences
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) announced management will participate in November investor conferences in 2025.
Events: Guggenheim Healthcare Innovation Conference on Nov 11, 2025 at 8:00 AM ET (fireside chat) and Jefferies London Healthcare Conference on Nov 17, 2025 at 4:30 PM GMT (presentation). Live webcasts will be available in the Investors section of the company website and replays will be available for at least 30 days. Management will also hold one-on-one investor meetings during the conferences.
Positive
- None.
Negative
- None.
News Market Reaction – CDTX
In the Oct 28 session, CDTX gained 5.16%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.
Details are as follows:
Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 11, 2025
Time: 8:00 AM ET
Format: Fireside Chat
Event: Jefferies London Healthcare Conference
Date: November 17, 2025
Time: 4:30 PM GMT
Format: Presentation
The live webcast for the events can be accessed in the Investors section on the Company’s website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
